Hedra Therapeutics Inc.
Hedra Therapeutics Inc. is developing small-molecule neurosteroid modulators designed to address severe mood crises triggered by hormonal transitions, such as peripartum depression and perimenopausal mood instability. The company's platform uses agentic systems to map, predict, and precisely modulate the biological pathways driving mood disorders, enabling interventions that adapt to each patient's neuroendocrine state for rapid onset and durable efficacy.
- Drug Discovery & Therapeutics
- Healthcare Technology
- Biotechnology
- Artificial Intelligence
- AI Agents
Funding
Founders
Founder details are not available yet.
Product
Problem
Millions of people experience severe mood crises triggered by hormonal transitions, yet existing treatments often act too slowly, provide incomplete relief, or fail to address the underlying neuroendocrine drivers. Traditional approaches do not adapt to an individual's changing biological state, leaving patients without effective support during their most vulnerable moments.
Solution
Hedra Therapeutics Inc. is redefining emotional regulation by engineering small-molecule neurosteroid modulators that target the hormonal transitions underlying mood instability. The company's platform applies agentic systems to map, predict, and precisely modulate the biological pathways that drive mood disorders, enabling interventions that evolve with each patient's neuroendocrine state. Each therapy is designed for rapid onset and durable efficacy, helping patients restore balance, resilience, and a renewed sense of control. By combining deep neuroscience with adaptive intelligence, Hedra aims to deliver treatments that act swiftly and bring lasting relief to those navigating hormonally driven mood and stress disorders.
Target Audience
Primary customers are patients experiencing hormonally driven mood and stress disorders, including those with peripartum depression, premenstrual dysphoric disorder, and perimenopausal mood instability, as well as the psychiatrists and women's health providers who treat them.
Features
- Small-molecule neurosteroid modulators engineered for rapid onset and durable efficacy
- Agentic systems that map, predict, and precisely modulate mood-related biological pathways
- Adaptive platform that evolves interventions based on individual neuroendocrine state
- Focus on hormonal transitions that trigger severe mood crises, including peripartum and perimenopausal periods
- Therapies designed for accessibility across hormonally driven mood and stress disorders